Inflammatory Bowel Disease and Thromboembolic Events

Centro Hospitalar Tondela-Viseu149 enrolled

Overview

The main objective was to demonstrate the existence and importance of hypercoagulability in patients with IBD, by determining the prevalence of changes in coagulation parameters and evaluating the impact of these changes on the occurrence of thromboembolic events.

Study Type

OBSERVATIONAL

Enrollment

149

Conditions

Inflammatory Bowel Diseases Thromboembolism Coagulation Disorder

Interventions

No intervention was madeOTHER

No intervention was made

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with 18 years of age or older, diagnosed with IBD, followed at a gastroenterology consultation at Centro Hospitalar Tondela-Viseu, between November 2016 and April 2017. Exclusion Criteria: * Individuals with other risk factors for TE (severe hepatic or renal failure, valvular heart disease, atrial fibrillation, heart failure or cardiomyopathy, pregnancy, and oral anticoagulants or heparin at the baseline).

Locations (1)

Centro Hospitalar Tondela Viseu

Viseu, Portugal

Outcomes

Primary Outcomes

Prevalence of thromboembolic events in IBD

To evaluate the coagulation parameters and the prevalence of thromboembolic events in IBD patients

Time frame: 36 months

Coagulation parameters variations in IBD

To investigate the correlation between coagulation parameters and disease phenotype and activity.

Time frame: 36 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.